--- title: "Novartis Q4 FY25 operating income rises to USD 3.62 billion, up 21%" type: "News" locale: "en" url: "https://longbridge.com/en/news/274761472.md" datetime: "2026-02-04T06:00:51.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/274761472.md) - [en](https://longbridge.com/en/news/274761472.md) - [zh-HK](https://longbridge.com/zh-HK/news/274761472.md) --- > Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274761472.md) | [繁體中文](https://longbridge.com/zh-HK/news/274761472.md) # Novartis Q4 FY25 operating income rises to USD 3.62 billion, up 21% Novartis AG reported fourth quarter (Q4) net sales of USD 13.34 billion, reflecting a 1 percent increase. Operating income for the period reached USD 3.62 billion, up 2 percent. Net income for the quarter was USD 2.40 billion, with earnings per share (EPS) at USD 1.26. For the full year (FY) 2025, Novartis AG posted net sales of USD 54.53 billion, up 8 percent. Operating income for the year was USD 17.64 billion, an increase of 21 percent. Net income rose to USD 13.97 billion, representing a 17 percent increase, and EPS was USD 7.21, up 22 percent. Novartis AG highlighted strategic pipeline developments during the period, including the proposed acquisition of Avidity, which is expected to close in the first half of the year. The company noted it remains focused on four core therapeutic areas: cardiovascular-renal-metabolic, immunology, neuroscience, and oncology, while prioritizing investments in emerging technology platforms such as gene and cell therapy, radioligand therapy, and xRNA. The company confirmed it achieved its 2025 Patient Access Targets under its sustainability-linked bond, resulting in no interest rate adjustment for the bond, which will continue to pay zero percent interest until its maturity in September 2028. As of Q4 2025, Novartis AG’s long-term credit rating stands at Aa3 with Moody’s Ratings and AA- with S&P Global Ratings. Looking ahead to 2026, Novartis AG expects net sales to grow in the low single-digit range, while core operating income is anticipated to decline in the low single-digit range, barring unforeseen events. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novartis AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001162862-en) on February 04, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) ### Related Stocks - [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md) - [Vanguard Health Care ETF (VHT.US)](https://longbridge.com/en/quote/VHT.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/en/quote/IBBQ.US.md) - [Novartis AG (NOT.DE)](https://longbridge.com/en/quote/NOT.DE.md) - [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/en/quote/PBE.US.md) - [Novartis AG (NVS.US)](https://longbridge.com/en/quote/NVS.US.md) - [ARK Genomic Revolution ETF (ARKG.US)](https://longbridge.com/en/quote/ARKG.US.md) - [ALPS Medical Breakthroughs ETF (SBIO.US)](https://longbridge.com/en/quote/SBIO.US.md) - [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md) - [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md) - [State Street®HlthCrSelSectSPDR®ETF (XLV.US)](https://longbridge.com/en/quote/XLV.US.md) - [iShares US Pharmaceuticals ETF (IHE.US)](https://longbridge.com/en/quote/IHE.US.md) - [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md) - [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md) ## Related News & Research - [Teva Pharmaceutical Gets US FDA Approval for Prolia Biosimilar; Xoliar Biosimiliar Applications Accepted in US, Europe](https://longbridge.com/en/news/281026919.md) - [BMS, Novartis, Gilead, Iovance dinged in CBER untitled letters](https://longbridge.com/en/news/281059389.md) - [EXCLUSIVE: Penny Stock Scienture Reports Revenue Surge, Expanding Market Access In 2025](https://longbridge.com/en/news/281015927.md) - [Ultragenyx clears IND for UX016 to advance Phase 1/2 GNEM study funded by patient group](https://longbridge.com/en/news/281024362.md) - [Arcutis Reports New Positive Phase 2 Results For ZORYVE Cream In Infant Atopic Dermatitis](https://longbridge.com/en/news/280971278.md)